Pharmacokinetic bias analysis of an association between clinical thyroid disease and two perfluoroalkyl substances

• Main Authors: Michael W. Dzierlenga, Bruce C. Allen, Harvey J. Clewell, III, Matthew P. Longnecker
• Format: Article
• Language: English
• Published: Elsevier 2020-08-01
• Series: Environment International
• Subjects: PBPK modeling; Pharmacokinetics; Perfluoroalkyl substances; Clinical thyroid disease; Reverse causality
• Online Access: http://www.sciencedirect.com/science/article/pii/S0160412019349694

Exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) has been associated with the occurrence of thyroid disease in some epidemiologic studies. We hypothesized that in a specific epidemiologic study based on the National Health and Nutrition Examination Survey, the association of clinical thyroid disease with serum concentration of PFOA and PFOS was due to reverse causality. Thyroid hormone affects glomerular filtration, which in turn affects excretion of PFOA and PFOS. We evaluated this by linking a model of thyroid disease status over the lifetime to a physiologically based pharmacokinetic model of PFOA and PFOS. Using Monte Carlo methods, we simulated the target study population and analyzed the data using multivariable logistic regression. The target and simulated populations were similar with respect to age, estimated glomerular filtration rate, serum concentrations of PFOA and PFOS, and prevalence of clinical thyroid disease. The analysis showed little or no evidence of bias from the hypothesized mechanism. The largest bias was for the fourth quartile of PFOA in females, with an odds ratio of 0.93 (95% CI, 0.90, 0.97). The reported odds ratio of clinical thyroid disease for this group was 1.63 (1.07, 2.47), and if it were corrected for the bias would have been 1.74 (1.14, 2.65). Our results suggest that little of the reported association in the target study was due to reverse causality.